SKYE vs. REPL, ESPR, RGNX, AURA, CMPS, CRVS, YMAB, AQST, VIGL, and CMPX
Should you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include Replimune Group (REPL), Esperion Therapeutics (ESPR), REGENXBIO (RGNX), Aura Biosciences (AURA), COMPASS Pathways (CMPS), Corvus Pharmaceuticals (CRVS), Y-mAbs Therapeutics (YMAB), Aquestive Therapeutics (AQST), Vigil Neuroscience (VIGL), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry.
Skye Bioscience vs. Its Competitors
Replimune Group (NASDAQ:REPL) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.
Replimune Group currently has a consensus price target of $6.50, suggesting a potential upside of 20.82%. Skye Bioscience has a consensus price target of $15.50, suggesting a potential upside of 345.40%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Skye Bioscience is more favorable than Replimune Group.
92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by insiders. Comparatively, 4.5% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Replimune Group has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500.
In the previous week, Replimune Group had 20 more articles in the media than Skye Bioscience. MarketBeat recorded 30 mentions for Replimune Group and 10 mentions for Skye Bioscience. Replimune Group's average media sentiment score of 0.27 beat Skye Bioscience's score of -0.08 indicating that Replimune Group is being referred to more favorably in the media.
Replimune Group's return on equity of -69.34% beat Skye Bioscience's return on equity.
Skye Bioscience is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.
Summary
Replimune Group and Skye Bioscience tied by winning 7 of the 14 factors compared between the two stocks.
Get Skye Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skye Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:SKYE) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access